On Friday, ImmunityBio Inc (NASDAQ: IBRX) opened lower -7.80% from the last session, before settling in for the closing price of $4.87. Price fluctuations for IBRX have ranged from $3.10 to $10.53 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 195.19% over the past five years. Company’s average yearly earnings per share was noted 30.10% at the time writing. With a float of $159.58 million, this company’s outstanding shares have now reached $670.87 million.
Let’s look at the performance matrix of the company that is accounted for 628 employees. In terms of profitability, gross margin is -26.45%, operating margin of -4900.23%, and the pretax margin is -8018.24%.
ImmunityBio Inc (IBRX) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of ImmunityBio Inc is 77.10%, while institutional ownership is 9.89%.
ImmunityBio Inc (IBRX) Latest Financial update
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -0.38 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -0.18) by -0.2. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.16 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 30.10% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -1.70% during the next five years compared to 1.17% growth over the previous five years of trading.
ImmunityBio Inc (NASDAQ: IBRX) Trading Performance Indicators
Check out the current performance indicators for ImmunityBio Inc (IBRX). In the past quarter, the stock posted a quick ratio of 2.64. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 393.54.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.89, a number that is poised to hit -0.17 in the next quarter and is forecasted to reach -0.63 in one year’s time.
Technical Analysis of ImmunityBio Inc (IBRX)
ImmunityBio Inc (NASDAQ: IBRX) saw its 5-day average volume 5.94 million, a positive change from its year-to-date volume of 4.98 million. As of the previous 9 days, the stock’s Stochastic %D was 15.83%. Additionally, its Average True Range was 0.54.
During the past 100 days, ImmunityBio Inc’s (IBRX) raw stochastic average was set at 30.24%, which indicates a significant increase from 3.16% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 72.79% in the past 14 days, which was lower than the 86.70% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.12, while its 200-day Moving Average is $5.25. Nevertheless, the first resistance level for the watch stands at $4.81 in the near term. At $5.13, the stock is likely to face the second major resistance level. The third major resistance level sits at $5.32. If the price goes on to break the first support level at $4.30, it is likely to go to the next support level at $4.11. The third support level lies at $3.79 if the price breaches the second support level.
ImmunityBio Inc (NASDAQ: IBRX) Key Stats
There are currently 696,831K shares outstanding in the company with a market cap of 2.88 billion. Presently, the company’s annual sales total 620 K according to its annual income of -583,200 K. Last quarter, the company’s sales amounted to 1,050 K and its income totaled -134,560 K.
